<DOC>
	<DOCNO>NCT00338351</DOCNO>
	<brief_summary>Three dose primary vaccination study reactogenicity immunogenicity healthy infant 6-12 week age time first vaccination Streptococcus pneumoniae .</brief_summary>
	<brief_title>Safety Immunogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' 10-valent Pneumococcal Conjugate Vaccine .</brief_title>
	<detailed_description>Test group : 2 ( 120 subjects/group ) . 1 group receive GSK Biologicals ' 10-valent pneumococcal conjugate vaccine + DTPa combine vaccine ; Control group receive GSK Biologicals ' Havrix + DTPa combine vaccine</detailed_description>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female , include , 6 12 week ( 4290 day ) age time first vaccination , free obvious health problem write informed consent obtain parent/guardian subject . Use investigational nonregistered drug vaccine study vaccine within 30 day precede first dose study vaccine , plan use study period . Planned administration/ administration vaccine foreseen study protocol period start one month first dose vaccine ( ) entire study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>